Featured Studies & Reports
Academic-Industry Partnerships for Biopharmaceutical Research & Development: Advancing Medical Science in the U.S.
30 April, 2012 - A new study by the Tufts University Center for the Study of Drug Development explores partnerships between biopharmaceutical companies and academic medical centers (AMCs). The report describes the various types of partnership models that exist and identifies next generation academic-industry collaboration models emerging from the public-private-partnership paradigm. The report concludes that academic-industry partnerships are growing in number and importance as “the translational gap between discovery and clinical development has become increasingly difficult to bridge.”
PhRMA 2012 Profile Highlights $49.5 Billion Investment In Research and Development in 2011
12 April, 2012 - PhRMA recently released its annual Pharmaceutical Industry Profile which provides important information about the biopharmaceutical sector, including the latest medical advances, the impact of these companies on the economy and the future of innovation. The report points to the biopharmaceutical sector's standing as the most research-intensive U.S. industry, noting the continued focus on cutting-edge research.
Orphan Drug Development Strong 25 Years after the Orphan Drug Act
21 November, 2011 - A study recently reprinted by Nature Reviews Drug Discovery reported that since the passage of the U.S. Orphan Drug Act of 1983, 1,892 drugs have received orphan drug-designation and 326 have received marketing approval, representing more than 200 rare diseases. Since the mid-1990s there has been a nearly tripling in the annual number of orphan drug designations from 57 in 1996 to 165 in 2008.
Personalized Medicine Is Playing a Growing Role in Biopharmaceutical Development Pipelines
16 November, 2010 - A new report from the Tufts Center for the Study of Drug Development finds that biopharmaceutical companies are committed to researching and developing personalized medicines. The data show, for the first time, the extent to which companies are embracing this new research.
